Study to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib Capsule
Status:
Completed
Trial end date:
2021-05-10
Target enrollment:
Participant gender:
Summary
This study is a multicenter, Phase I, open-label, randomized, 2-sequence, 2-treatment,
2-period, crossover, bioequivalence study with single doses of acalabrutinib administered
orally in healthy participants. The study is designed to demonstrate the bioequivalence of
acalabrutinib tablet (Treatment A) compared with marketed acalabrutinib capsule (Treatment B)
in the fasted state.